July 18, 2014 (Shareholders Foundation) - An investigation on behalf of investors of Lannett Company, Inc. (NYSE:LCI) shares over potential securities laws violations by Lannett Company and certain of its directors and officers in connection certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Lannett Company, Inc. (NYSE:LCI) concerning whether a series of statements by Lannett regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Lannett Company, Inc. reported that its Total Revenue rose from $106.83 million for the 12 months period that ended on June 30, 2011 to $151.05 million for the 12 months period that ended on June 30, 2013 and that its Net Loss of $0.28 million for the 12 months period that ended on June 30, 2011 turned into a Net income of $13.32 million for the 12 months period that ended on June 30, 2013.

Shares of Lannett Company, Inc. (NYSE:LCI) grew from $4.16 per share in November 2012 to as high as $51.19 per share on July 2, 2014.

Then on July 16, 2014, Lannett Company, Inc. announced that, 'it has received interrogatories and subpoena from the State of Connecticut Office of the Attorney General concerning its investigation into pricing of digoxin. According to the subpoena, the Connecticut Attorney General is investigating whether anyone engaged in any activities that resulted in (a) fixing, maintaining or controlling prices of digoxin or (b) allocating and dividing customers or territories relating to the sale of digoxin in violation of Connecticut antitrust law.' Shares of Lannett Company, Inc. declined from over $51 per share in early July 2014 to as low as $36.86 per share during July 17, 2014.

On July 18, 2014, NYSE:LCI shares closed at $38.19 per share.